Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Published byHarjanti Irawan Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy."— Presentation transcript:

1 Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Shown is geographic atrophy progression by fundus autofluorescence in the CFI+ (risk-allele carriers) and CFI− (risk-negative) subgroups (rs ) with monthly lampalizumab treatment versus sham treatment. (A) In the CFI+ subpopulation, there was a 44% reduction in geographic atrophy area progression with monthly lampalizumab treatment versus sham control at month 18. (B) Representative fundus autofluorescence images at baseline and month 18 for the CFI+ subpopulation. Relative geographic atrophy area progression is shown for the sham and lampalizumab monthly treated groups. (C) In the CFI− subpopulation, there was no apparent benefit with monthly lampalizumab treatment versus sham control at month 18. The least-squares mean was estimated from a linear mixed-effect model that included baseline geographic atrophy area as a continuous variable, time point as a categorical variable, treatment, time-by-treatment interaction, and baseline geographic atrophy category (≥10 mm2 versus <10 mm2). Vertical bars are 95% CIs of the least-squares mean. In parentheses, n corresponds to the number of patients at the 6-, 12-, and 18-month time points, respectively. Brian L. Yaspan et al., Sci Transl Med 2017;9:eaaf1443 Published by AAAS

Download ppt "Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 2. Increased Aβ plaque load in 16-month-old APP/PS1;C3 KO mice.

Fig. 2. Increased Aβ plaque load in 16-month-old APP/PS1;C3 KO mice.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.
Fig. 2 LYM attractor metagene.

Fig. 2 LYM attractor metagene.
PREMIER: Rate of hypertension at 18 months

PREMIER: Rate of hypertension at 18 months
Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.
Fig. 6. C3 deficiency resulted in partial sparing of neuron loss in hippocampal CA3 in 16-month-old APP/PS1 mice. C3 deficiency resulted in partial sparing.

Fig. 6. C3 deficiency resulted in partial sparing of neuron loss in hippocampal CA3 in 16-month-old APP/PS1 mice. C3 deficiency resulted in partial sparing.
Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,

Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.

Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.
Fig. 1. Bacterial communities shift during AD disease progression.

Fig. 1. Bacterial communities shift during AD disease progression.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.

Similar presentations

Ads by Google